Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified
2011 (English)In: Cancer Letters, ISSN 0304-3835, E-ISSN 1872-7980, Vol. 313, no 2, 145-153 p.Article in journal (Refereed) Published
We investigated the efficacy and safety of single-agent pegylated liposomal doxorubicin (PLD) as first-line treatment for elderly women with advanced breast cancer and evaluated predictive markers for response and toxicity. Twenty-five women >= 65 years received 40 mg/m(2) PLD every 28 days. Time to treatment failure (TTF), response rate, time to progression (TTP) and overall survival (OS) was calculated. The ABCB1 single nucleotide polymorphisms (SNP), tumor MRN complex, and TOPOII alpha were analyzed. A mean of 7.4 cycles PLD were administered and TIT was 5.5 months and OS 20.6 months. ABCB1 SNPs were found to correlate to both efficacy and toxicity, while tumor expression of the MRN complex and TOPOII alpha correlated to TTP. PLD is a safe and effective treatment for elderly breast cancer patients. Also potential predictive markers were identified.
Place, publisher, year, edition, pages
2011. Vol. 313, no 2, 145-153 p.
Anthracycline, Elderly, Genotype, Metastatic breast cancer, MRN complex, Topoisomerase II alpha
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:kth:diva-55230DOI: 10.1016/j.canlet.2011.07.017ISI: 000297895800004ScopusID: 2-s2.0-82655187163OAI: oai:DiVA.org:kth-55230DiVA: diva2:474346
FunderSwedish Research Council
QC 201201092012-01-092012-01-022012-01-09Bibliographically approved